公众号 / 文章腹部泌尿生殖CT

病例332:酪氨酸激酶抑制剂所致肠淋巴管扩张症

Case 332: Tyrosine Kinase Inhibitor-induced Intestinal Lymphangiectasia.
PubMed 文献 · Radiology · 2024-01-01

65岁男性,肉瘤样肾细胞癌右肾切除术后,因复发接受最大剂量帕唑帕尼及立体定向体部放疗,用药7个月后行腹盆静脉期增强CT监测。患者用药1个月后出现腹泻,需持续洛哌丁胺控制,伴腹痛但无发热,白蛋白正常、总蛋白偏低。

要点

  • 酪氨酸激酶抑制剂(如帕唑帕尼)治疗期间出现腹泻、低蛋白血症时,需警惕药物所致肠淋巴管扩张症。
  • 本例在帕唑帕尼治疗7个月后行腹盆静脉期增强CT监测,用药1个月即出现腹泻并需洛哌丁胺维持。
  • 血清白蛋白正常(3.9 g/dL)而总蛋白偏低(6.1 g/dL),提示蛋白丢失性肠病可能。

核心结论

  • 病例332展示一例65岁男性肉瘤样肾细胞癌患者,在最大剂量帕唑帕尼治疗及立体定向体部放疗后出现腹泻和低总蛋白血症,最终诊断为酪氨酸激酶抑制剂所致肠淋巴管扩张症。

研究设计与样本

  • 病例报告(Case 332),单例65岁男性患者,接受腹盆静脉期增强CT监测;无对照组。

关键影像表现/征象

  • 患者有肉瘤样肾细胞癌右肾切除史,复发灶位于下腔静脉旁。
  • 帕唑帕尼最大剂量治疗开始后1个月出现腹泻,需持续洛哌丁胺控制,伴腹痛不适,无发热,生命体征正常。
  • 白细胞计数正常(5100/μL),分类计数均正常;血清白蛋白正常(3.9 g/dL),总蛋白偏低(6.1 g/dL)。
  • 血清氯98 mmol/L(参考范围100-108 mmol/L),碱性磷酸酶121 U/L(参考范围45-115 U/L)。
  • 监测影像为腹盆静脉期增强CT。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

History A 65-year-old male patient with a history of sarcomatoid renal cell carcinoma and prior right nephrectomy developed recurrent disease adjacent to the inferior vena cava. The patient underwent surveillance imaging 7 months after initiation of treatment with maximum-dose pazopanib and less than 1 month after completing a 2-month regimen of palliative stereotactic body radiation therapy to the right nephrectomy bed and site of recurrence. (Stereotactic body radiation therapy was initiated 5 months after pazopanib treatment was initiated.) One month after initiating treatment with pazopanib and 6 months before the surveillance imaging, the patient developed diarrhea and required ongoing treatment with loperamide to control symptoms. He denied any fatigue, mouth sores, or extremity pain, but described some abdominal pain and discomfort associated with the diarrhea. He was not experiencing any fevers, and vital signs were normal. White blood cell count was normal at 5100/μL (5.1 ×109/L) (reference range, 4200-10 200/μL [4.2-10.2 ×109/L]), with all components of the differential count also being normal. A normal serum albumin level of 3.9 g/dL (39 g/L) (reference range, 3.5-5.0 g/dL [35-50 g/L]) and low serum total protein level of 6.1 g/dL (61 g/L) (reference range, 6.3-7.9 g/dL [63-79 g/L]) were noted. A comprehensive metabolic panel was performed, indicating a serum chloride level of 98 mmol/L (reference range, 100-108 mmol/L) and an alkaline phosphatase level of 121 U/L (2.02 μkat/L) (reference range, 45-115 U/L [0.75-1.92 μkat/L]). The patient underwent surveillance imaging with contrast-enhanced CT of the abdomen and pelvis in the venous phase.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Adler C, Menias C. Case 332: Tyrosine Kinase Inhibitor-induced Intestinal Lymphangiectasia. Radiology. 2024. PMID: 39718494. doi:10.1148/radiol.232148

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。